Purpose or Objective: Short-course radiotherapy (25 Gy in five fractions) was recently shown in a multi-national randomized phase III clinical trial to be non-inferior to a commonly used regimen (40 Gy in 15 fractions) in elderly and/or frail patients with glioblastoma multiforme, with no difference in overall survival (OS) and progression free survival (PFS). This study compared the cost-effectiveness of the two regimens.
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Material and Methods:
The direct unit costs of imaging, radiotherapy (RT), and dexamethasone were collected in equitable US dollars (USD) from the five primary contributing countries to the trial, representing 88% of all patients accrued (n = 86) between 2010 and 2013. Effectiveness was measured by the restricted mean overall survival (RMOS) and progression free survival (RMPFS). Irwin's restricted mean method was used to calculate mean survival time in the presence of censoring, and life-years gained and PFS gained. The incremental cost-effectiveness ratio (ICER) was calculated as: Cost per life-year gained = (Difference in direct costs between short-course RT and commonly used RT) ÷ (Difference in life-years gained between short-course RT and commonly used RT). Indirect costs were also estimated for comparison.
Results:
There was no OS difference between the two studied populations. The median OSs for the short-course and commonly used RTs were 8.2 (6.1-10.3) and 7.7 (5.5-9.9) months, respectively. Median PFSs were also not different. The differences in the RMOS and the ICER, however, were +0.11 life-years and -USD 3307 per life-year gained, respectively. The differences in the RMPFS and the ICER were +0.02 PFS and -USD 19030, respectively. The negative ICER values indicated improvement in direct cost in addition to life-years gained with the short-course RT. Indirect cost comparison also identified improved survival-to-treatment time ratio and reduced cost for patients and care-givers with short-course RT.
Conclusion:
The direct cost account for ICER of -USD 3307 per life-year gained and -USD 19030 per PFS gained indicates that the short-course RT is less costly and more effective compared to the commonly used RT. Indirect cost is also improved with the short-course RT.
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